Xcellerex is a developer and producer of turn-key bio-manufacturing systems and production-scale bioreactors based around single-use components. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bioproducts, such as vaccines, yeast, and insulins.
Financial terms were not disclosed. The acquisition is expected to close in the second quarter of 2012.
Xcellerex, based in Marlborough, Mass., employs approximately 135 people and had revenues of approximately $50 million in 2011.
Related Articles on Company Acquisitions:
ZOLL Medical to be Acquired by Tokyo’s Asahi Kasei for $2.2B
Boston Scientific to Acquire Cameron Health
Nuance to Acquire Medical Transcription Company Transcend Services for $300M
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
